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of systemic treatment, measured at 3, 6, and 12 months, 
were compared among the 4 groups using generalized lin-
ear mixed-effects models.  Results: Between March 2011 and 
December 2014, 334 patients were included; 151 received 
conventional systemic therapeutics, 145 biologics, 13 com-
bined treatment, and 25 had a therapy adaptation. With re-
gard to the absolute PASI, neither the biologic cohort nor the 
combined treatment cohort significantly differed from the 
conventional systemic therapeutics cohort. The odds of 
reaching PASI90 was significantly increased with combined 
therapy compared to conventional systemic therapeutics
( p = 0.043) and decreased with a higher body mass index
( p = 0.041). At visits 3 and 4, the PASI was generally lower 
than at visit 2 (visit 3 vs. visit 2,  p = 0.0019; visit 4 vs. visit 2,
 p < 0.001). After 12 months, patients with biologic treatment 
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 Abstract 
 Background: Randomized controlled trials have shown the 
efficacy of systemic treatments in moderate-to-severe pso-
riasis. Clinical outcomes in psoriasis patients under real-
world conditions are less well understood.  Objective: This 
study compared Psoriasis Area and Severity Index (PASI) and 
Dermatological Life Quality Index (DLQI) improvement in all 
psoriasis patients registered in the Swiss Dermatology Net-
work for Targeted Therapies. We asked whether outcomes 
differed between 4 treatment strategies, namely biologic 
monotherapy versus conventional systemic monotherapy, 
versus combined biologic and conventional systemic drugs, 
and versus therapy adaptation (switching from one type to 
another).  Methods: PASI and DLQI within 1 year after onset 
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had a significantly lower DLQI than those with conventional 
systemic therapeutics ( p = 0.001).  Conclusion: This study 
suggests that after 1 year of treatment, biologics are supe-
rior in improving the subjective disease burden compared to 
conventional systemic drugs.  © 2017 S. Karger AG, Basel 
 Introduction 
 Of about 8.2 million people living in Switzerland, up 
to 360,000 suffer from psoriasis  [1, 2] , and between 8,200 
and 32,400 may have moderate-to-severe psoriasis. The 
latter condition has a profound impact on the quality of 
life of patients and their respective risk to develop or 
worsen diseases of civilization such as cardiovascular 
events  [3, 4] . Although randomized controlled trials have 
shown efficacy of most systemic treatments  [5–7] , pro-
found knowledge about long-term outcomes and optimal 
treatment strategies in specific patients under real-world 
conditions are lacking in Switzerland. The Swiss Derma-
tology Network for Targeted Therapies (SDNTT) registry 
was established in 2011 to study the efficacy and safety of 
approved systemic therapies and patient-reported mea-
sures in real-life settings over time  [8] . In contrast to ran-
domized clinical trials, patient registries have less strin-
gent inclusion criteria and allow to follow heterogeneous 
patient populations with varying disease severity and 
medications for long periods of time  [9, 10] . We were par-
ticularly interested to compare the development of the 
PASI (Psoriasis Area and Severity Index) and DLQI (Der-
matological Life Quality Index) within the first year of 
onset of treatment in all Swiss psoriasis patients included 
in the SDNTT who were treated with biologics only, bio-
logics and conventional systemic therapeutics (simulta-
neously) or therapy adaptation (switching from one type 
to the other) with those who were treated with conven-
tional systemic therapeutics only. The SDNTT is a non-
interventional observational registry based on an elec-
tronic case report form provided by the Centre of Excel-
lence for Health Services Research in Dermatology 
(CVderm, Competenzzentrum Versorgungsforschung in 
der Dermatologie) at the University Medical Center 
Hamburg Eppendorf, Germany. The documentation is 
managed using a patient-based database as a registry. 
 Patients and Methods 
 For further details, see the supplementary materials (for all on-
line suppl. material, see www.karger.com/doi/10.1159/000455042 
 [11–18] ( Fig. 1 ).
Sufficient for PASI analysis
(n = 283):
Conventional treatment (n = 121)
Biologic treatment (n = 127)
Combined treatment (n = 10)
Adapted therapy (n = 25)
Sufficient for analysis of patient characteristics
(n = 334):
Conventional treatment (n = 151)
Biologic treatment (n = 145)
Combined treatment (n = 13)
Adapted therapy (n = 25)
Sufficient for PASI90, and
PASI75 analysis (n = 281):
Conventional treatment (n = 119)
Biologic treatment (n = 127)
Combined treatment (n = 10)
Adapted therapy (n = 25)
SDNTT registry
(n = 335)
Not sufficient for analysis
(n = 1)
Sufficient for DLQI analysis
(n = 266):
Conventional treatment (n = 114)
Biologic treatment (n = 119)
Combined treatment (n = 10)
Adapted therapy (n = 23)
 Fig. 1. Flowchart of Patients and Methods. Number of patients in the SDNTT registry included in the analysis in 
general and specifically in each of the outcome analyses by treatment cohort. 
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 Results 
 Out of the 334 patients included in the SDNTT registry 
( Fig. 1 ), 145 received biologics (60 adalimumab, 50 uste-
kinumab, 31 etanercept, 4 infliximab) and 151 convention-
al systemic therapeutics (107 methotrexate, 22 fumaric acid 
esters and 19 other drugs or PUVA;  Table 1 ). The average 
age was 47.1 years (SD 15) with only 39.2% women. The 
average body mass index (BMI) was 27.0 (SD 6.4), and the 
mean prior disease duration was 15 years (SD 13.5). Pso-
riasis arthritis was present in 23.9% over all groups. 
 Primary End Point PASI 
 Neither the biologic nor the combined treatment cohort 
significantly differed from the conventional systemic ther-
apeutics cohort with regard to absolute PASI ( Table 2 ). 
 Patients with therapy adaptation had on average a 
higher PASI than those with conventional systemic thera-
peutics ( p = 0.003). At visits 3 and 4, the PASI was gener-
ally lower than at visit 2 (visit 3 vs. visit 2,  p = 0.0019; vis-
it 4 vs. visit 2,  p < 0.001). The development of PASI values 
within 12 months was similar in all cohorts, as indicated 
by the non-significant interaction terms between treat-
ment cohorts and visits. Moreover, there was a significant 
positive association between the PASI at baseline (visit 1) 
and the PASI at visits 2–4. The results from the statistical 
model of the log-transformed PASI are visualized on the 
original scale for a “model patient” in  Figure 2 .
 Secondary End Points PASI75 and PASI90 
 Both the odds (and thus the probability) of a PASI90 
and PASI75 were significantly increased at visits 3 and 4 
compared to visit 2 (Appendix Tables). The odds of 
PASI75 was significantly increased with higher values of 
the PASI at baseline ( p < 0.001), whereas this effect was 
non-significant for the PASI90. This indicates that pa-
tients with higher baseline PASI were more likely to ex-
perience a reduction of the PASI by at least 75%. More-
over, the odds of PASI90 was significantly decreased with 
a higher BMI ( p = 0.041) and increased with combined 
therapy compared to conventional systemic therapeutics 
( p = 0.043). The results for the binary end points PASI75 
and PASI90 are visualized as probabilities for a “model 
patient” in  Figures 3 and  4 .
 Secondary End Point DLQI 
 Patients with biologic treatment reached a lower DLQI 
than those with conventional systemic therapeutics ( p = 
 Table 1.  Baseline characteristics of patients in the 4 cohorts
Con. Bio. Comb. Ada. p
n 151 145 13 25
Mean age (SD), years 46.9 (16.0) 46.6 (14.4) 50.5 (15.6) 49.6 (12.4) 0.685
Mean body size (SD), cm 170.9 (8.9) 171.4 (9.5) 174.5 (10.2) 173.5 (9.4) 0.369
Mean body weight (SD), kg 82.1 (20.5) 82.6 (21.5) 90.8 (26.1) 86.1 (21.2) 0.459
Mean body mass index (SD) 28.1 (6.5) 28.0 (6.2) 29.6 (7.6) 28.6 (6.9) 0.824
Mean years since diagnosis (SD) 15.7 (13.0) 19.7 (14.1) 20.5 (10.5) 17.5 (12.5) 0.091
Mean baseline DLQI (SD) 10.6 (6.8) 11.1 (7.6) 11.6 (9.1) 15.0 (7.0) 0.067
Mean baseline PASI (SD) 9.0 (5.9) 10.7 (7.3) 14.8 (8.9) 11.7 (7.5) 0.007
Gender female, n (%) 57 (37.7) 65 (44.8) 4 (30.8) 5 (20.0) 0.097
PSO arthropathy yes, n (%) 15 (10.2) 45 (31.0) 5 (38.5) 14 (56.0) <0.001
Baseline medication, n (%) <0.001
Adalimumab 0 (0.0) 60 (41.4) 0 (0.0) 2 (8.0)
Combination 6 (4.1) 0 (0.0) 13 (100.0) 5 (20.0)
Cyclosporin 5 (3.4) 0 (0.0) 0 (0.0) 2 (8.0)
Etanercept 0 (0.0) 31 (21.4) 0 (0.0) 1 (4.0)
Fumaric acid 22 (14.9) 0 (0.0) 0 (0.0) 3 (12.0)
Infliximab 0 (0.0) 4 (2.8) 0 (0.0) 1 (4.0)
Methotrexate 107 (72.3) 0 (0.0) 0 (0.0) 8 (32.0)
Retinoid 8 (5.4) 0 (0.0) 0 (0.0) 0 (0.0)
Ustekinumab 0 (0.0) 50 (34.5) 0 (0.0) 3 (12.0)
 Note that due to missing values, the number of measurements is lower than the total number (top row) for 
some characteristics. Con., conventional; Bio., biologics; Comb., combination; Ada., adaptation; PSO, psoriasis.
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0.001) while patients with therapy adaptation had a high-
er DLQI than those with conventional systemic therapeu-
tics ( p = 0.003). The higher the DLQI at baseline, the high-
er remained the DLQI during treatment ( p < 0.001). The 
DLQI at visits 3 and 4 was on average lower than at visit 
2 (visit 3 vs. visit 2,  p < 0.001; visit 4 vs. visit 2,  p = 0.0026). 
The results from the statistical model on the log-trans-
formed DLQI are again visualized on the original scale for 
a “model patient” in  Figure 5 .
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 Table 2.  Effect size estimates with 95% confidence intervals (CI) for all predictors in the linear mixed-effects model on the log(PASI + 1)
Estimate 95% CI t p
Intercept 0.490 0.219, 0.760 3.50 <0.001
log(PASI at visit 1 + 1) 0.382 0.274, 0.490 6.86 <0.001
Age 0.003 –0.002, 0.008 1.04 0.2986
Female vs. male –0.048 –0.198, 0.102 –0.62 0.5350
BMI 0.008 –0.004, 0.019 1.30 0.1948
Biologics vs. conventional –0.100 –0.287, 0.087 –1.04 0.2989
Combined vs. conventional –0.173 –0.629, 0.282 –0.74 0.4622
Adaptation vs. conventional 0.490 0.178, 0.802 3.04 0.0025
Visit 3 vs. visit 2 –0.235 –0.380, –0.089 –3.13 0.0019
Visit 4 vs. visit 2 –0.329 –0.515, –0.142 –3.42 <0.001
Biologics vs. conventional at v3 vs. v2 0.000 –0.203, 0.203 0.00 0.9965
Combined vs. conventional at v3 vs. v2 0.051 –0.466, 0.566 0.19 0.8488
Adaptation vs. conventional at v3 vs. v2 –0.125 –0.458, 0.208 –0.73 0.4671
Biologics vs. conventional at v4 vs. v2 0.164 –0.093, 0.420 1.24 0.2162
Combined vs. conventional at v4 vs. v2 0.277 –0.441, 0.995 0.75 0.4547
Adaptation vs. conventional at v4 vs. v2 –0.275 –0.662, 0.112 –1.38 0.1692
 v2, visit 2; v3, visit 3; v4, visit 4. The model included 283 patients.
 Fig. 2. Development of the PASI under dif-
ferent therapies. Model-based fitted values 
of the PASI on the original scale together 
with bayesian 95% credible intervals at vis-
its 2–4 for all cohorts. The fitted values rep-
resent a male patient of median age (47.5 
years), median BMI (27.0) and median 
baseline PASI (8.9, shown as dashed hori-
zontal line). 
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 Fig. 3. Development of PASI75 under dif-
ferent therapies. Fitted values of the prob-
ability of PASI75 together with bayesian 
95% credible intervals at visits 2–4 for all 
cohorts. The fitted values represent a male 
patient of median age (47.5 years), median 
BMI (27.0) and median baseline PASI 
(8.9). 
 Fig. 4. Development of PASI90 under dif-
ferent therapies. Fitted values of the prob-
ability of PASI90 together with bayesian 
95% credible intervals at visits 2–4 for all 
cohorts. The fitted values represent a male 
patient of median age (47.5 years), median 
BMI (27.0) and median baseline PASI 
(8.9). 
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 Discussion 
 This study investigated PASI and DLQI changes over 12 
months after initiation of a systemic therapy in all psoriasis 
patients registered in the SDNTT registry from May 2011 
to December 2014. The patient number in this study was 
relatively low compared to older registries of larger coun-
tries  [19] ; however, the results reflect the real-world situa-
tion of registered and treated patients in Switzerland. With-
in 12 months after the start of therapy, patients with mod-
erate-to-severe psoriasis who were treated with biologics or 
combined therapy showed essentially equivalent develop-
ments of PASI values compared to those who were treated 
with conventional systemic therapeutics only. In compari-
son to those on conventional systemic therapeutics, a larg-
er proportion of patients on biologics reached PASI75 and 
PASI90; however, the differences were not significant over 
the 12-month period. This could be due to the interrater 
variation by different investigators for the PASI assessment 
and a direct consequence that the PASI has a low resolution 
below values of 5  [13] ( Fig. 2 ). As expected, patients who 
had to adapt treatment did not reach comparable PASI val-
ues within 12 months, as this cohort understandably repre-
sents more difficult-to-treat patients. Moreover, the limited 
number of patients under combined treatment had an in-
creased probability to reach PASI90. However, real-world 
outcome data on combined therapy are rare, some authors 
concluded that combined therapy might have at least some 
potential benefit in patients with joint involvement, metho-
trexate toxicity or in cases of monotherapy failure  [20] .
 In contrast to PASI development patients treated with 
biologics reached significantly lower DLQI values within 
12 months compared to those treated with conventional 
systemic therapeutics. As in the biologic patient group 
psoriatic arthritis was slightly overrepresented ( Table 1 ), 
the greater DLQI reduction might reflect the patient ben-
efit of biologics on improvement of joint complaints. Pre-
sumably reduced monitoring visits, lower injection fre-
quencies and higher drug tolerability of biologically treat-
ed patients could be feasible arguments for the better 
DLQI improvements. Previous studies comparing objec-
tive and subjective assessments in psoriasis patients on 
biologics and conventional systemic agents have been 
rather limited  [21] . In line with our results one report also 
revealed more pronounced DLQI improvements in pa-
tients receiving biologics for 12 months compared to 
those who were on conventional systemic therapeutics 
 [22] . We consider this finding important since the deci-
sion to initiate biologic treatment for physicians and 
health insurances still seems to be more strongly depen-
dent on PASI values than on DLQI scores  [23] . As stated 
in the recently published Swiss S1 guidelines and also 
based on our own results, DLQI values should be criti-
cally taken into account particularly in patients with low-
13
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Conventional
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Combined
Adaptation
Months after baseline
D
LQ
I
 Fig. 5. Development of the DLQI under 
different therapies. Model-based fitted val-
ues of the DLQI on the original scale to-
gether with bayesian 95% credible intervals 
at visits 2–4 for all cohorts. The fitted val-
ues represent a male patient of median age 
(47.5 years), median BMI (27.0) and me-
dian baseline DLQI (10, shown as dashed 
horizontal line). 
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er PASI values suffering from severe involvement of dif-
ficult-to-treat locations such as the nails, scalp, genitals, 
palmoplantar areas or joint involvement and in those pa-
tients complaining of severe pruritus. This study has po-
tential limitations. Due to missing values on outcomes 
and covariates used in the statistical models, the number 
of patients included in the analysis was relatively low 
compared to other registries  [24] . However, we believe 
that our failure to detect significant differences regarding 
the primary end point PASI between either biologics or 
combined therapy and conventional systemic therapeu-
tics is rather due to the small and clinically irrelevant ef-
fect sizes (e.g., PASI for biologics <0.5 points lower than 
for conventional systemic therapeutics after 3 months, at 
visit 2;  Fig. 2 ) than due to the relatively small sample size.
 The strength of this register-based study from Switzer-
land is that it analyses the subjective and objective disease 
activity under real-world conditions using robust statisti-
cal models that account for the effects of important patient 
characteristics, which reduce the problem of confound-
ing. Nevertheless, some characteristics that might con-
tribute to the outcome as well, such as details of the pso-
riasis location, were not captured in the SDNTT registry. 
 Taken together, this study shows that after 1 year of 
treatment, biologics are superior in improving the subjec-
tive disease burden compared to conventional systemic 
drugs.
 Acknowledgements 
 The authors wish to thank all those who helped to create the 
SDNTT registry, all patients and all health care personnel and the 
SDNTT steering board. 
 Statement of Ethics 
 This research study protocol was ethically conducted in accor-
dance with the World Medical Association Declaration of Hel-
sinki and has been approved by the University Hospital of Basel 
Ethical Review Board, Switzerland. The project was conducted 
with informed written consent from all patients. 
 Disclosure Statement  
 The SDNTT registry has received financial support from Ab-
bvie, Jansen and Pfizer. The sponsors had no access to data. Data 
collection, study design, interpretation, and analysis have been 
carried out with the authors’ independence. All authors have par-
ticipated in industry-sponsored meetings, received travel support, 
or served as speaker or investigator for one or more of the follow-
ing companies: AbbVie, Janssen, Pfizer, Novartis, Celgene, MSD. 
The authors certify that they have no relevant affiliations with or 
involvement in any organization or entity with any financial inter-
est (such as honoraria, employment, stock ownership, or other eq-
uity interest, and expert testimony or patent-licensing arrange-
ments) that would contribute to any bias in the subject matter dis-
cussed in this paper.
OR 95% CrI z p
Intercept 0.317 0.163, 0.630 –2.90 0.0037
PASI at visit 1 (scaled) 2.309 1.614, 3.281 3.92 <0.001
Age (scaled) 0.832 0.584, 1.162 –0.99 0.3226
Female vs. male 1.255 0.648, 2.477 0.61 0.5404
BMI (scaled) 0.927 0.665, 1.296 –0.43 0.6696
Biologics vs. conventional 1.666 0.680, 4.015 1.03 0.3044
Combined vs. conventional 4.079 0.454, 37.412 1.17 0.2427
Adaptation vs. conventional 0.309 0.060, 1.634 –1.36 0.1741
Visit 3 vs. visit 2 3.253 1.531, 6.740 2.69 0.0071
Visit 4 vs. visit 2 4.486 1.600, 11.190 2.71 0.0067
Biologics vs. conventional at v3 vs. v2 1.114 0.381, 3.168 0.19 0.8525
Combined vs. conventional at v3 vs. v2 0.467 0.026, 7.996 –0.49 0.6217
Adaptation vs. conventional at v3 vs. v2 1.347 0.222, 8.174 0.30 0.7615
Biologics vs. conventional at v4 vs. v2 0.730 0.197, 2.784 –0.44 0.6620
Combined vs. conventional at v4 vs. v2 0.331 0.006, 16.844 –0.51 0.6068
Adaptation vs. conventional at v4 vs. v2 1.936 0.241, 15.165 0.59 0.5546
 Appendix 
 Table to Figure 3 
 Estimates of the odds ratios (OR) with bayesian 95% credible intervals (CrI) for all predictors in the general-
ized linear mixed-effects model on the PASI75. The model included 281 patients. v2, visit 2; v3, visit 3; v4, visit 4.
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 Table to Figure 4 
 Estimates of the odds ratios (OR) with bayesian 95% credible intervals (CrI) for all predictors in the general-
ized linear mixed-effects model on the PASI90. The model included 281 patients. v2, visit 2; v3, visit 3; v4, visit 4.
 Table to Figure 5 
Effect size estimates with 95% confidence intervals (CI) for all predictors in the linear mixed-effects model on 
the log(DLQI + 1). The model included 266 patients. v2, visit 2; v3, visit 3; v4, visit 4. 
 
OR 95% CrI z p
Intercept 0.019 0.006, 0.056 –4.74 <0.001
PASI at visit 1 (scaled) 1.586 1.028, 2.489 1.89 0.059
Age (scaled) 0.783 0.505, 1.237 –1.06 0.289
Female vs. male 1.516 0.628, 3.706 0.91 0.363
BMI (scaled) 0.618 0.382, 1.013 –2.05 0.041
Biologics vs. conventional 2.126 0.561, 8.534 1.13 0.260
Combined vs. conventional 17.082 1.550, 203.568 2.02 0.043
Adaptation vs. conventional 0.819 0.065, 11.858 –0.17 0.867
Visit 3 vs. visit 2 3.914 1.280, 12.491 2.34 0.019
Visit 4 vs. visit 2 11.374 3.130, 45.604 3.34 <0.001
Biologics vs. conventional at v3 vs. v2 1.708 0.409, 7.171 0.73 0.466
Combined vs. conventional at v3 vs. v2 0.271 0.016, 4.894 –0.86 0.391
Adaptation vs. conventional at v3 vs. v2 1.041 0.060, 17.305 0.03 0.975
Biologics vs. conventional at v4 vs. v2 0.434 0.067, 2.421 –0.95 0.344
Combined vs. conventional at v4 vs. v2 0.079 0.002, 2.385 –1.26 0.208
Adaptation vs. conventional at v4 vs. v2 0.638 0.033, 12.001 –0.32 0.752
Estimate 95% CI t p
Intercept 0.588 0.259, 0.918 3.45 <0.001
log(DLQI at visit 1 + 1) 0.425 0.301, 0.549 6.65 <0.001
Age 0.001 –0.006, 0.008 0.16 0.8735
Female vs. male –0.034 –0.239, 0.171 –0.32 0.7466
BMI 0.006 –0.009, 0.022 0.79 0.4312
Biologics vs. conventional –0.417 –0.661, –0.173 –3.31 0.0010
Combined vs. conventional –0.248 –0.838, 0.343 –0.81 0.4176
Adaptation vs. conventional 0.642 0.223, 1.060 2.97 0.0032
Visit 3 vs. visit 2 –0.398 –0.570, –0.225 –4.49 <0.001
Visit 4 vs. visit 2 –0.314 –0.514, –0.113 –3.04 0.0026
Biologics vs. conventional at v3 vs. v2 0.227 –0.014, 0.469 1.82 0.0689
Combined vs. conventional at v3 vs. v2 0.287 –0.298, 0.872 0.95 0.3411
Adaptation vs. conventional at v3 vs. v2 0.132 –0.257, 0.520 0.66 0.5112
Biologics vs. conventional at v4 vs. v2 0.255 –0.030, 0.541 1.73 0.0839
Combined vs. conventional at v4 vs. v2 –0.137 –0.894, 0.625 –0.35 0.7270
Adaptation vs. conventional at v4 vs. v2 –0.203 –0.642, 0.237 –0.90 0.3714
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